Literature DB >> 21878605

Antiretroviral therapy and adverse skeletal effects.

Gianluigi Fabbriciani, Giuseppe V L De Socio, Marco Massarotti.   

Abstract

Mesh：

Year:  2011        PMID： 21878605      PMCID： PMC3257996          DOI： 10.4065/mcp.2011.0341

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  4 in total

1.  Efavirenz and bone health.

Authors:  Gianluigi Fabbriciani; Giuseppe Vittorio L De Socio
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

Review 2.  Update on medications with adverse skeletal effects.

Authors:  Caroline J Davidge Pitts; Ann E Kearns
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

3.  Continuous antiretroviral therapy decreases bone mineral density.

Authors:  Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

4.  Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.

Authors:  Christoph A Fux; Andri Rauch; Mathew Simcock; Heiner C Bucher; Bernard Hirschel; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Luigia Elzi; Hansjakob Furrer
Journal:  Antivir Ther       Date:  2008
  4 in total
  1 in total

1.  Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.

Authors:  Giuseppe Vittorio L De Socio; Gianluigi Fabbriciani; Marco Massarotti; Salvatore Messina; Enisia Cecchini; Bianca Marasini
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-05-04       Impact factor: 2.576
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.